Helena Fritz is a Research Engineer at Lund University, affiliated with the Division of Molecular Hematology (DMH), RNA and Stem Cell Biology, StemTherapy, and LUCC (Lund University Cancer Centre). Her work spans cancer biology, RNA metabolism, and neuroanatomy, contributing to UN Sustainable Development Goals like SDG 3 (Good Health and Well-being). Specializes in Axl RTK signaling in renal cancer Investigates RNA splicing and tRNA fragmentation mechanisms Develops neuroanatomical imaging techniques for insect brains Her research explores cross-disciplinary themes including retrotransposon-driven inflammation, epigenetic regulation in hematological malignancies, and tissue clearing technologies. Recent publications in Cell Reports and Molecular Cell highlight her contributions to RNA biology and cancer progression. Key collaborations include work with international teams on tumor suppression networks and stem cell therapies. She contributes to translational medicine through studies on drug resistance mechanisms in renal cancer.
James Burke is an Assistant Professor in the Department of Molecular Medicine at the University of Florida, leading the Burke Lab at the UF Scripps campus in Jupiter, Florida. His research focuses on RNA biology during pathogenic viral infections including dengue, Zika, SARS-CoV-2, and influenza A. His educational background includes: Postdoctoral Fellow (2017-2022) at University of Colorado Boulder Ph.D. (2010-2016) from University of Texas at Austin B.S. Biochemistry (2006-2009) from University of North Texas Dr. Burke's research centers on host RNA decay pathways, particularly the OAS/RNase L system, and how viruses manipulate these mechanisms. His lab combines biochemistry, molecular biology, and advanced microscopy to study ribonucleoprotein granule formation, mRNA processing during infection, and viral evasion tactics. Key discoveries include RNase L-induced RNA sequestration bodies, nuclear-cytoplasmic signaling during infection, and the role of RNA in granule integrity. Analysis of his 15 most recent publications reveals a dominant focus on RNase L-mediated host shutoff mechanisms across flaviviruses and coronaviruses. His work demonstrates how viral infections trigger widespread mRNA decay, disrupt nuclear export, and induce novel granule structures - with significant implications for antiviral therapy development. Dr. Burke serves as Principal Investigator on an active NIH NIGMS grant (awarded September 2023) titled "Understanding the OAS/RNase L pathway during pathogenic viral infections," which examines molecular mechanisms of this critical antiviral pathway. The Burke Lab operates at the UF Scripps Biomedical Research campus, utilizing cutting-edge microscopy and molecular techniques to investigate RNA-virus interactions within live cells. The lab environment emphasizes interdisciplinary approaches to understanding host-pathogen dynamics at the RNA level.
Danae Schulz is an Associate Professor of Biology at Harvey Mudd College, where she conducts research on the African trypanosome, a protozoan parasite that causes sleeping sickness in humans and nagana in cattle. She teaches courses including Molecular Biology Lab, Topics in Biochemistry and Molecular Biology, Molecular Immunology, Introduction to Biology, and Biology Laboratory. Her educational background includes: B.A. in Biology from Tufts University B.M. in Violin Performance from New England Conservatory Ph.D. in Molecular and Cell Biology from University of California Berkeley Postdoctoral Research Fellowship at Rockefeller University Visiting Assistant Professor position at Bard College Danae's research focuses on understanding how African trypanosomes reprogram themselves to adapt as they move between the differing environments of the tsetse fly midgut and the mammalian bloodstream. Her work aims to identify the molecular mechanisms that drive these life cycle transitions, with an eye toward manipulating these adaptations to generate new therapies for trypanosome infections. She employs a combination of molecular biology techniques, genomic approaches, and computational analysis in her research. Analysis of her recent publications reveals a strong focus on chromatin biology, epigenetic regulation, and gene expression control in trypanosomes, with increasing translational applications. Her work spans from fundamental molecular mechanisms of parasite adaptation to potential therapeutic approaches targeting bromodomain proteins and other regulatory factors. The research shows progression from basic characterization of molecular pathways to more applied studies seeking therapeutic interventions, with significant undergraduate student involvement across all projects. Her notable scientific achievement includes: NSF CAREER grant for research "Characterizing molecular mechanisms that drive life cycle transitions in the African trypanosome" Danae actively mentors undergraduate students in her research lab, with students contributing as co-authors on numerous publications. Her lab has received funding from the NSF to support student researchers and a technician, enabling more students to engage in meaningful research experiences. She is also involved in multidisciplinary efforts to detect and counteract emerging pathogens, including participation in the Mitigating Zoonotic Threats conference sponsored by the Research Corporation for Science Advancement and the U.S. Department of Agriculture, where she proposed innovative approaches to parasite resistance using CRISPR technology. The Schulz Lab uses the African trypanosome as a model system to understand how organisms reprogram themselves in response to changes in their environment. The lab combines bench science with computational analysis, taking advantage of Harvey Mudd students' strong skills in computer programming. Current research directions include investigating how parasites adapt to different environments, with potential applications for fighting diseases like African trypanosomiasis, which affects regions of Sub-Saharan Africa where the disease is endemic with an estimated economic burden of over $2 billion per year due to livestock losses.
Dr. David Meierhofer is the Head of Mass Spectrometry Facility at the Max Planck Institute for Molecular Genetics in Berlin, Germany, a position he has held since March 2012. With a PhD in Genetics from the University of Salzburg (completed December 2005), he previously served as a Senior Post-Doctoral Researcher at MPIMG (2009-2012) and conducted postdoctoral research at the University of California Irvine's Department of Biological Chemistry (2006-2009). Dr. Meierhofer's primary research interests focus on mitochondrial pathologies , employing proteomic and metabolomic approaches to investigate human mitochondrial dysfunctions. His work centers on understanding the regulatory networks and interplay between proteins and metabolites in mitochondrial disorders, with particular emphasis on post-translational modifications. His expertise spans Mass Spectrometry, Proteomics, Metabolomics, and Energy Metabolism, with significant contributions to understanding mitochondrial involvement in diseases including cancer and diabetes. Analysis of Dr. Meierhofer's recent publications reveals a strong focus on mitochondrial function in disease contexts, particularly in neurological disorders, liver transplantation, and metabolic diseases. His work frequently employs multi-omics approaches combining proteomics and metabolomics to uncover molecular mechanisms. The research spans fundamental mitochondrial biology to clinical applications, especially in organ transplantation viability assessment and neurodegenerative conditions. With 189 publications and over 4,500 citations, Dr. Meierhofer has established himself as a significant contributor to mitochondrial research and mass spectrometry applications in biomedical science. His work demonstrates consistent productivity and increasing impact in the field. As Head of the Mass Spectrometry Facility, Dr. Meierhofer leads a critical resource for proteomic and metabolomic analysis at MPIMG, supporting numerous research groups with advanced analytical capabilities. His facility plays a key role in enabling cutting-edge research on mitochondrial disorders and related pathologies through high-resolution mass spectrometry analysis.
Jonathan Watts is a Professor at the UMass Chan Medical School's RNA Therapeutics Institute and holds multiple academic positions across the T.H. Chan School of Medicine and Morningside Graduate School of Biomedical Sciences. His primary focus is on RNA-based therapies, gene editing technologies, and nucleic acid delivery systems. Watts earned his BS in Chemistry from Dalhousie University and his PhD in Bio-organic Chemistry from McGill University. His research integrates molecular biology, drug design, and clinical application to develop treatments for genetic disorders. Key areas include antisense oligonucleotides for neurodegenerative diseases (e.g., ALS), CRISPR-Cas9 and prime editing systems, and viral vector engineering for in vivo gene therapy. Notable contributions include work on APOBEC3 inhibitors, dNTP optimization for prime editing, and mitigating oligonucleotide toxicity in the CNS. Watts has authored over 150 publications in top journals like *Nature Biotechnology*, *Lancet*, and *Molecular Therapy*. His collaborations span academia and industry, including NIH-funded programs for somatic cell genome editing. He actively contributes to translational research, aiming to bridge nucleic acid chemistry with clinical outcomes for conditions like fragile X syndrome, glioblastoma, and SARS-CoV-2 infection.
Virginia Panara is a Research Fellow in the Department of Organismal Biology at Uppsala University, Sweden, affiliated with the Evolutionary Biology Centre (EBC). Her research focuses on molecular mechanisms of lymphatic vascular development using zebrafish models, with emphasis on gene regulatory networks and evolutionary perspectives. She maintains an active publication record in high-impact journals including Nature and Development. Her primary research interests encompass developmental biology, lymphatic system regulation, evolutionary developmental biology (Evo-Devo), molecular genetics of endothelial cell specification, and zebrafish modeling. She employs advanced methodologies such as confocal microscopy, single-cell RNA sequencing, and computational image analysis to investigate transcriptional control mechanisms involving genes like prox1a and Dmrt , particularly examining cis-regulatory elements and cell migration dynamics in vascular patterning. Analysis of her 2018-2025 publications reveals a cohesive research trajectory centered on lymphatic endothelial cell identity, with increasing methodological sophistication from phylogenetic studies to multi-omic approaches. Key themes include the relationship between lymphatic and secondary vascular systems in fish, epigenetic regulation of cell lineages, and topographically distinct genetic control of vessel formation, demonstrating interdisciplinary integration of developmental, evolutionary, and systems biology perspectives. No scientific awards are documented in the available information. There is no available data regarding her advisory roles, graduate students, or research grant funding. Dr. Panara collaborates with multiple research groups at Uppsala University, including teams led by Katarzyna Koltowska (vascular development) and Ralf Janssen (evolutionary biology), contributing to a dynamic research environment focused on uncovering molecular principles of endothelial cell identity through the Evolutionary Biology Centre's infrastructure.
Dr. Tim Harvey-Samuel is a Lecturer in Arthropod Genetics and Group Leader at Keele University's School of Life Sciences. He holds a PhD from the University of Oxford/Oxitec Ltd, where he researched genetically engineered methods for controlling agricultural insect pests. His postdoctoral work at the Pirbright Institute focused on gene-drive systems and insect sex determination. His research develops sustainable genetic control approaches for agricultural and human-health pests like mosquitoes and moths. His research integrates molecular biology, genetic modification, and synthetic biology to manage pests such as Culex quinquefasciatus, Aedes albopictus, and Plutella xylostella. He specializes in CRISPR-based gene drives, germline transformation, and sex determination pathways. Publications focus on CRISPR applications, gene drives, and vector control, with recent work emphasizing field applicability and ecological impact. Trends include optimization of gene-drive efficiency, pest population suppression, and vector-pathogen interactions. No awards or student advisees are documented. He leads a research group and collaborates globally to advance genetic pest management.
Michael Reese is a Professor in the Department of Pharmacology at UT Southwestern Medical Center, where he has been since joining in 2013. He holds a B.S. in Molecular Biophysics & Biochemistry from Yale University (1998) and a Ph.D. in Biophysics from UCSF (2006), with postdoctoral training at Stanford University under John Boothroyd. His research focuses on understanding how the parasite Toxoplasma gondii manipulates host cell signaling networks, employing techniques from genetics, cell biology, biophysics, and structural biology. Key areas include pseudokinase function, host-pathogen interactions, and parasite virulence mechanisms. Education: B.S., Molecular Biophysics & Biochemistry, Yale University, 1998 Ph.D., Biophysics, University of California, San Francisco, 2006 Research Interests: Dr. Reese's lab investigates Toxoplasma gondii's strategies to hijack host cellular machinery, particularly focusing on pseudokinases, membrane dynamics, and immune evasion. Recent work highlights the role of MAPK pathways and protein kinase signaling in parasite survival and pathogenesis. His studies integrate structural biology with functional genomics to uncover novel antiparasitic targets. Labs/Teams: Reese Lab at UT Southwestern focuses on cutting-edge research into parasitic mechanisms, with active projects on Toxoplasma's molecular biology and host interactions. The lab maintains a website dedicated to their research findings and resources.
Jennifer Kohler is an Associate Professor in the Department of Biochemistry at UT Southwestern Medical Center, leading the Kohler Lab. Her research focuses on developing chemical biology tools to study glycosylation's roles in biological systems, including glycans' interactions with pathogens like cholera toxin and their impact on cellular processes. She completed her Ph.D. at Yale University and postdoctoral training at UC Berkeley. Key research areas include O-GlcNAc modifications, sialic acid pathways, and the structural biology of glycoconjugates. Her lab has pioneered photocrosslinking sugar analogs to study transient glycan-mediated interactions, advancing understanding of cholera toxin mechanisms and nuclear transport. Collaborations span glycobiology, infectious disease, and metabolic disorders. Her work bridges biochemistry and clinical applications, with a focus on glycoscience's underappreciated potential in medicine and biotechnology. Current projects address glycosylation's role in intestinal epithelial biology and glycobiology tools' application to cancer and metabolic disorders. Publications highlight discoveries in cholera toxin receptor dynamics, O-GlcNAc signaling, and glycan engineering. The lab is part of the Simmons Cancer Center, integrating glycoscience with oncology research.
Christian Diercks, PhD is an Assistant Professor in the Department of Chemistry at the Scripps Research Institute. His research focuses on reticular chemistry, covalent organic frameworks (COFs), and metal-organic frameworks (MOFs), with emphasis on their applications in catalysis, energy storage, and materials science. He holds a Ph.D. from the University of California, Berkeley. Key research areas include the design of CO2 reduction catalysts using reticular tuning of active sites, structural engineering of 2D/3D COFs, and development of functional frameworks for environmental and biomedical applications. His work bridges molecular and materials-level chemistry to create next-generation materials with tailored properties. Notable contributions include studies on framework topologies (e.g., catenated polyhedra, graphene-linked COFs), electrocatalytic CO2 reduction systems, and functionalization strategies for porous materials. His research spans interdisciplinary areas of organic chemistry, nanotechnology, and energy materials.
Dr. Irosha Nawarathne is an Associate Professor of Chemistry at Lyon College, located in Batesville, Arkansas. She earned her Bachelor's degree (First Class Honors) in Chemistry from the University of Colombo, Sri Lanka, and her PhD in Bioorganic Chemistry from Michigan State University. Her research focuses on drug discovery, particularly targeting multi-drug resistant Mycobacterium tuberculosis and lung cancer therapies. She leads an undergraduate research team developing novel rifamycins and exploring naphthoquinone derivatives for cancer treatment. Education: BSc (University of Colombo), PhD (Michigan State University) Grants: Funded by NIH/NIGMS (P20 GM103429), Arkansas INBRE, and FutureFuel Chemical Company Key Projects: Rifamycin modifications, lung cancer therapeutics, food chemistry analysis Publications: Over 15 peer-reviewed manuscripts and multiple conference presentations Research interests include biocatalytic methods for natural product modification, antibiotic development, and applying organic chemistry to biomedical challenges. Her lab emphasizes undergraduate involvement in drug discovery, with students contributing to publications and winning awards at regional and national conferences. She is a coordinator for Lyon's Science Outreach Program and advises the Order of the Tartans Mortar Board Chapter. Her work is supported by grants totaling over $700,000, enabling state-of-the-art instrumentation and student participation in conferences.
Matheus Froeyen is an Associate Professor at the Faculty of Pharmaceutical Sciences of KU Leuven, affiliated with the Department of Pharmaceutical and Pharmacological Sciences and the Medicinal Chemistry unit at Rega Institute. His work focuses on computer-aided molecular modeling and synthetic nucleic acids for drug design. Member of Faculty Council (senior academic staff) Member of Departmental Council Member of Interfaculty Council for Global Development Research spans molecular modeling , kinase inhibitors , and nucleic acid analogs . He leads projects on phosphonate XNA development (2019-2023), hepatitis B virus inhibition (2017-2022), and GAK inhibitors for cancer treatment. Recent Publications (2024-2025) Covers synthetic nucleic acid modeling , anticancer steroidal compounds , and NS3/4A protease inhibitors for drug-resistant hepatitis C. Utilizes computational methods, chemical synthesis, and directed evolution approaches. Teaching K0B03A Organische Chemie I K0B20A Organische Chemie II Labs & Collaborations Works at Rega Institute’s MEDICINAL CHEMISTRY unit and co-develops the Ducque (X)NA model builder software.
Matteo Castelli is a Fixed-term Researcher (Type A) in Microbiology and Clinical Microbiology at the Università Vita Salute San Raffaele. His work focuses on viral pathogenesis, antiviral strategies, and infectious disease mechanisms, with expertise in SARS-CoV-2, hepatitis C virus (HCV), and herpes simplex virus (HSV). He holds a position within the Department of Medicine, contributing to research on viral dynamics, immune evasion, and molecular mechanisms of viral infections. His teaching responsibilities include courses in Microbiology and Clinical Microbiology for medical students, emphasizing practical laboratory skills and professional competencies. Castelli's research outputs include studies on viral mutations, antibody responses, and therapeutic interventions. Notable areas of focus are SARS-CoV-2 variant evolution, HCV vaccine targets, and HSV reactivation modeling. His work bridges basic science with clinical applications, including drug repurposing and organ-on-a-chip models for viral infections. Despite listed teaching assignments and active publication record through 2025, no specific scientific awards or grant details are documented in the provided text.
Professor Espen Rimstad is a leading virologist at the Norwegian University of Life Sciences (NMBU), affiliated with the School of Veterinary Science and the Virology Department. He leads a research group of 10–12 scientists focused on viral infections in fish, particularly in aquaculture species such as Atlantic salmon and rainbow trout. His research interests include: Viral diseases in fish (e.g., pancreas disease, cardiomyopathy syndrome, HSMI) Vaccinology, including plant-made and mRNA-based vaccines Pathogenesis of piscine orthoreovirus (PRV), salmonid alphavirus (SAV), and infectious salmon anaemia virus (ISAV) Fish immunology and host-pathogen interactions Emerging viral threats in aquaculture His recent publications reflect a strong trend in developing novel vaccine platforms, understanding immune responses in fish, and characterizing viral pathogenesis using advanced molecular and transcriptomic techniques. Many of his studies focus on improving fish health and aquaculture sustainability through science-based solutions. Scientific contributions include: Over 329 publications with high citation impact Leadership in national risk assessments (e.g., VKM) Development of inactivated and live attenuated vaccines Pioneering work on mRNA-LNP delivery in fish He has advised numerous students and researchers, though specific names are not listed. His work is supported by major research projects such as ViVaFish (Fish Virus Vaccines). He collaborates extensively with institutions like the Norwegian Veterinary Institute and international partners. He is also involved in ethical and environmental assessments related to aquaculture practices. Rimstad is active in multiple laboratories and research networks, contributing to both fundamental and applied aspects of fish virology. His lab at NMBU is a hub for innovation in aquatic animal health, with ongoing work on viral diagnostics, vaccine development, and disease mitigation strategies.
Dr. Dominic Jones is a Researcher at Newcastle University, specializing in prostate and breast cancer biology, molecular mechanisms of hormone receptors, and transcriptional regulation. His work spans CRISPR engineering, RNA splicing, and pathway modulation. Research Focus: Hormonal oncology, gene regulation, and targeted cancer therapies. Collaborations: Extensive co-authorship with experts in prostate cancer, including Dr. Luke Gaughan, Professor Craig Robson, and Dr. Sirintra Nakjang. His contributions include defining splicing factor requirements for androgen receptor variants (2024), CRISPR-engineered cell lines for PARP inhibitor sensitivity (2019), and elucidating the role of Aurora A kinase in castrate-resistant models (2017). His research intersects molecular biology, genetics, and pharmacology to advance cancer treatments.
